Helix BioPharma Highlights L-DOS47 at World ADC
Company Announcements

Helix BioPharma Highlights L-DOS47 at World ADC

Story Highlights

Helix BioPharma (TSE:HBP) has released an update.

Helix BioPharma Corp. showcased its innovative L-DOS47 platform at the World ADC San Diego, underscoring its potential in treating hard-to-treat cancers by enhancing the immune system’s response. The company is advancing towards a Phase II study for non-small cell lung cancer and exploring broader applications across various cancer types.

For further insights into TSE:HBP stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Canadian Auto-Generated NewsdeskHelix BioPharma to Acquire Laevoroc’s Oncology Assets
TipRanks Canadian Auto-Generated NewsdeskHelix BioPharma Unveils Promising Cancer Treatment
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App